1. DCC-2618, a pan KIT and PDGFR switch control inhibitor, achieves proof-of-concept in a first-in-human study. (December 2016) Authors: Janku, F.; George, S.; Razak, A.; Gordon, M.; Brooks, D.; Flynn, D.G.; Kaufman, M.; Pitman, J.; Smith, B.; Somaiah, N.; Gerstenberger, E.; Westwood, D.; Rosen, O. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗